^
    Back
    Association details:
    Biomarker:MET exon 14 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:CKD-702 (c-MET inhibitor, EGFR antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO 2022
    Title:

    998P - A phase I study of CKD-702, an EGFR-cMET bispecific antibody, in advanced or metastatic non-small cell lung cancer (NSCLC)

    Published date:
    09/05/2022
    Excerpt:
    CKD-702 has a manageable safety profile related to EGFR and cMet inhibition, and showed preliminary response in patients with MET ex14 skipping.
    Trial ID:
    NCT04667975